RxDoctor Payments Data

Maria Diaz, OD

Optometrist · East Haven, CTNPI 1265408371

Payments from drug & device makers

$3,007in general payments, 2019–2025

Across 74 payments — averaging $40.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$360
  • Oyster Point Pharma, Inc.$347
  • Coopervision Inc.$334
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$315
  • AbbVie$314
  • Johnson & Johnson Surgical Vision, Inc.$263
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,000100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,007 in reported general payments places this provider in the 80th percentile of 574 optometrist providers in Connecticut.

See all optometrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$85,466
Medicare patients
286
Services billed
1,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine55$52,167
XiidraLifitegrast34$41,217
XdemvyLotilaner14$26,085
LumiganBimatoprost20$13,323
Loteprednol Etabonate14$1,778
Brimonidine Tartrate11$1,074
Tobramycin-DexamethasoneTobramycin/Dexamethasone19$904
Latanoprost87$521
Doxycycline Monohydrate15$465
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$199
Timolol Maleate12$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$314$65,49175 claims
Bausch & Lomb Americas Inc.Xiidra$360$41,21734 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$175$26,08514 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$315$1,77814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 574 optometrist providers in Connecticut.

Other optometrist in East Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →